Isaac E. Ciechanover Sells 600 Shares of Atara Biotherapeutics Inc (ATRA) Stock
Atara Biotherapeutics Inc (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 600 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $30.38, for a total value of $18,228.00. Following the completion of the sale, the chief executive officer now owns 743,675 shares of the company’s stock, valued at approximately $22,592,846.50. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Shares of Atara Biotherapeutics Inc (NASDAQ ATRA) traded down $0.75 during mid-day trading on Friday, reaching $27.50. The company’s stock had a trading volume of 655,000 shares, compared to its average volume of 1,469,842. Atara Biotherapeutics Inc has a 12-month low of $11.80 and a 12-month high of $30.90. The company has a market capitalization of $894.93, a P/E ratio of -7.93 and a beta of 1.27.
Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.97) by ($0.05). sell-side analysts forecast that Atara Biotherapeutics Inc will post -4 earnings per share for the current fiscal year.
ATRA has been the subject of a number of recent research reports. BidaskClub upgraded Atara Biotherapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, January 11th. Canaccord Genuity restated a “buy” rating on shares of Atara Biotherapeutics in a research report on Friday, December 29th. Goldman Sachs Group restated a “neutral” rating and issued a $20.00 target price on shares of Atara Biotherapeutics in a research report on Friday, October 6th. Jefferies Group restated a “buy” rating and issued a $30.00 target price on shares of Atara Biotherapeutics in a research report on Thursday, October 5th. Finally, Citigroup upgraded Atara Biotherapeutics from a “sell” rating to a “neutral” rating and set a $18.00 target price for the company in a research report on Wednesday, January 3rd. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Atara Biotherapeutics has an average rating of “Buy” and an average target price of $30.60.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.